URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31

UroGen Pharma Ltd.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$34.15−0.41 (-1.19%)

Close on Oct 19, 2026

Market cap: $1.72B
P/E (TTM): –
Dividend yield: –

UroGen Pharma Ltd. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q2 2026 2026-06-30	TTM Q1 2026 2026-03-31	TTM FY 2025 2025-12-31	TTM Q3 2025 2025-09-30	TTM Q2 2025 2025-06-30	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31	TTM Q3 2024 2024-09-30	TTM Q2 2024 2024-06-30	TTM Q1 2024 2024-03-31	TTM FY 2023 2023-12-31	TTM Q3 2023 2023-09-30	TTM Q2 2023 2023-06-30	TTM Q1 2023 2023-03-31	TTM FY 2022 2022-12-31	TTM Q3 2022 2022-09-30	TTM Q2 2022 2022-06-30	TTM Q1 2022 2022-03-31	TTM FY 2021 2021-12-31	TTM Q3 2021 2021-09-30	TTM Q2 2021 2021-06-30	TTM Q1 2021 2021-03-31	TTM FY 2020 2020-12-31	TTM Q3 2020 2020-09-30	TTM Q2 2020 2020-06-30	TTM Q1 2020 2020-03-31	TTM FY 2019 2019-12-31	TTM Q3 2019 2019-09-30	TTM Q2 2019 2019-06-30	TTM Q1 2019 2019-03-31	TTM FY 2018 2018-12-31	TTM Q3 2018 2018-09-30	TTM Q2 2018 2018-06-30	TTM Q1 2018 2018-03-31	TTM FY 2017 2017-12-31
Revenue	189	140	110	97	94	92	90	89	85	84	83	77	73	68	64	62	58	54	48	40	32	19	12	–	–	–	0.02	–	–	–	1.13	1.46	8.98	8.62	8.16
Cost of Revenue	17	14	12	12	11	9.48	8.88	8.70	8.61	8.82	9.36	9.34	8.99	8.39	7.65	6.98	6.20	5.79	5.16	4.22	3.29	1.91	1.01	–	–	–	–	–	–	–	1.80	2.09	1.33	1.01	0.60
Gross Profit	171	126	97	85	83	82	82	81	76	75	73	68	64	60	57	55	51	48	43	36	29	17	11	–	–	–	0.02	–	–	–	-0.68	-0.64	7.65	7.61	7.56
Research & Development	61	63	67	68	65	62	57	54	52	49	46	49	52	53	53	52	50	50	48	47	45	41	47	55	54	56	49	41	41	39	37	32	28	24	19
Selling, General & Admin	177	172	155	151	142	129	121	111	104	96	93	90	88	86	83	83	85	87	88	88	89	90	90	88	80	69	60	–	–	–	–	–	–	–	–
General & Administrative	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	60	53	50	46	40	30	22	14	8.81
Operating Expenses	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	109	94	91	85	77	63	50	38	28
Operating Income	-67	-108	-125	-133	-124	-108	-97	-84	-80	-69	-66	-71	-76	-79	-79	-79	-84	-88	-92	-100	-105	-114	-127	-139	-134	-126	-109	-94	-91	-86	-77	-63	-43	-30	-20
Interest & Investment Income	3.96	4.69	5.97	7.87	9.45	9.31	8.90	6.82	4.89	3.79	2.64	2.38	1.99	1.58	0.94	0.49	0.12	0.20	0.37	0.61	0.93	1.34	1.99	2.73	3.59	4.42	4.62	–	–	–	–	–	–	–	–
Other Non-Operating Income	-0.87	-0.90	-0.67	-0.73	-0.69	-0.14	-0.23	0.65	0.87	0.67	0.84	-0.04	-0.07	0.06	0.07	0.06	0.01	–	-0.15	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Investments	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-0.10	–	–	–	–
Pretax Income	-98	-138	-153	-162	-151	-135	-124	-111	-110	-100	-98	-104	-108	-110	-108	-107	-112	-112	-109	-109	-108	-113	-125	–	–	–	–	–	–	–	–	–	–	–	–
Income Tax Expense	-0.47	-5.09	0.08	3.00	4.15	3.17	2.83	4.04	3.94	3.95	3.92	0.76	1.47	1.45	1.76	2.20	1.49	1.77	1.45	3.69	3.69	–	3.37	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	-98	-133	-153	-165	-155	-138	-127	-115	-114	-104	-102	-105	-109	-112	-110	-109	-114	-113	-111	-113	-111	-117	-128	-137	-130	-121	-105	-90	-88	-84	-76	-62	-42	-30	-20
Preferred Dividends	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0.83
Net Income to Common	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-76	-62	-42	-30	-21
EPS (Basic)(per share)	-1.98	-2.75	-3.19	-3.46	-3.28	-3.05	-2.96	-2.92	-3.09	-3.30	-3.55	-4.26	-4.71	-4.86	-4.81	-4.83	-5.05	-5.04	-4.96	-5.07	-5.03	-5.30	-5.90	-6.40	-6.15	-5.79	-5.12	-2.49	-2.71	-2.77	-4.80	-4.04	-2.78	-2.34	-2.14
EPS (Diluted)(per share)	-1.98	-2.75	-3.20	-3.46	-3.28	-3.05	-3.00	-2.92	-3.09	-3.30	-3.73	-4.26	-4.71	-4.86	-4.81	-4.83	-5.05	-5.04	-4.96	-5.07	-5.03	-5.30	-5.90	-6.40	-6.15	-5.79	-5.12	-2.49	-2.71	-2.77	-4.80	-4.04	-2.78	-2.34	-2.14
Shares Outstanding (Basic, Weighted)(shares)	49	49	48	48	47	45	43	40	37	32	29	26	23	23	23	23	23	22	22	22	22	22	22	21	21	21	21	19	18	17	16	15	15	13	9.72
Shares Outstanding (Diluted, Weighted)(shares)	49	49	48	48	47	45	43	40	37	32	29	26	23	23	23	23	23	22	22	22	22	22	22	21	21	21	21	19	18	17	16	15	15	13	9.72
EBITDA	-66	-108	-125	-133	-123	-108	-96	-83	-79	-69	-65	-70	-75	-78	-78	-78	-83	-87	-91	-99	-105	-114	-126	-139	-133	-125	-109	-93	-91	-86	-77	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 90.8%
Operating margin: -35.3%
Net margin: -51.7%
Return on equity, FY2025: 268.6%

Financial strength

Current ratio: 3.80
Debt to equity: -1.43
Debt to assets: 74.7%
Cash to current liabilities: 127.8%

Valuation

P/E ratio: –
Price to sales: 9.12
Price to book: –
Dividend yield: –